Suman Atwal

Title: Innovator Spotlight: Suman Atwal

Introduction

Suman Atwal, an accomplished inventor based in San Jose, California, has made significant contributions to the field of pharmaceuticals. With a focus on targeting G-protein coupled receptors, his inventive work is poised to impact the treatment of various medical conditions.

Latest Patents

Atwal holds a patented disclosure for "Modulators of G-protein coupled receptors." This patent primarily features chemical entities that are capable of modulating glucagon-like peptide-1 receptor (GLP-1R) and gastric inhibitory polypeptide receptor (GIPR). The patent details how these chemical entities can be utilized for treating diseases where modulation of these receptors offers therapeutic benefits. This work highlights the potential for enhancing existing receptor activities, contributing to better treatment options for individuals suffering from related disorders.

Career Highlights

Currently, Suman Atwal is affiliated with Cannot Therapeutics, Inc., where he continues to explore the potentials of his innovative research. His work signifies a dedication to advancing medical science through targeted therapy solutions and a deep understanding of receptor signaling pathways.

Collaborations

Atwal collaborates with notable colleagues such as Johan Enquist and Shyam Krishnan. Together, they contribute to a research environment that fosters innovation and the development of new therapeutic agents. The synergy among these inventors enhances the scope of their work and broadens the impact of their inventions.

Conclusion

Suman Atwal's innovative spirit and dedication to enhancing medical treatments through his patents make him a noteworthy figure in the realm of pharmaceutical sciences. His contributions can potentially lead to significant advancements in treating conditions associated with G-protein coupled receptors, showcasing the vital role inventors play in healthcare innovation.